BioAtla, Inc.

BCAB

$1.74

+0.00%

2026-08-28 16:00:01 EDT+$0.00

Healthcare

Biotechnology

NASDAQ

Active Trading

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed ...

Price Action of BCAB

$1.74

+0.00%+$0.00

High—

Low—

52W High-97.6%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

BioAtla, Inc. is a clinical-stage oncology-focused biopharmaceutical company headquartered in San Diego, California, founded in 2007. The company’s core mission is to develop “safer and more effective” cancer drugs using its Conditionally Active Biologics™ (CAB) platform, which is designed to make antibody-based therapeutics more selectively active in relevant tumor contexts. ...BioAtla, Inc. is a clinical-stage oncology-focused biopharmaceutical company headquartered in San Diego, California, founded in 2007. The company’s core mission is to develop “safer and more effective” cancer drugs using its Conditionally Active Biologics™ (CAB) platform, which is designed to make antibody-based therapeutics more selectively active in relevant tumor contexts. This selectivity is intended to help reduce off-target activity and improve the therapeutic window versus conventional antibody approaches. From a products and pipeline perspective, BioAtla’s strategy centers on antibody-derived treatments in multiple solid tumor indications. The company’s experimental programs include CAB ADC (conditionally active biologic antibody-drug conjugate) candidates such as BA3011 and BA3021, which are being studied for solid malignancies including soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), melanoma, and ovarian cancer. BioAtla also advances BA3071, a conditionally active antibody targeting CTLA-4 intended to address a broad set of cancers, including renal cell carcinoma, NSCLC and small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Business-wise, BioAtla operates as a development-stage company where value creation is driven primarily by clinical progress, regulatory milestones, partnerships, and financing rather than near-term product revenue. Consistent with that stage, many financial metrics provided show negative profitability measures (e.g., margins and returns are negative), which is typical for early-stage biopharma companies investing heavily in research and development. The company reports ongoing investment in R&D (with R&D-to-revenue information provided) and uses cash and capital markets to support trials, manufacturing scale-up, and program development. In terms of cost structure and operations, the profile indicates a research-intensive business model with substantial operating and research spending relative to any current revenue. Key leadership includes Jay M. Short, Ph.D. (Chairman, CEO, and co-founder), reflecting founder-led continuity. Other senior roles cited include Richard Waldron (CFO) and Eric Sievers, M.D. (Chief Medical Officer). Overall, BioAtla’s “wishes” in the near term are aligned with advancing its CAB programs through clinical development, generating supportive clinical data for multiple solid tumor indications, and maintaining momentum toward potential approvals and commercialization paths—while managing the financial realities of a clinical-stage biopharmaceutical enterprise.ExpandCollapse

Founded

2007

Employees

CEO

Jay Short

Full Name

BioAtla, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

89.25%

Market Cap

$0.00B

Current Ratio

0.20

WACC

5.42%

ROIC

251.50%

Contact Information

https://www.bioatla.com

858 558 0708

11085 Torreyana Road, San Diego, CA 92121

Key Metrics of BCAB

Snapshot

Latest / TTM · 6 periods

Market Cap

$2.88M

ROCE

274.6%

EV / EBITDA

-0.25x

-458.1% YoY

FCF Yield

-815.5%

-671.2% YoY

Cash Conversion Cycle

-716.1d

Current Ratio

0.20

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of BCAB

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-4.2%

Net Margin

-370.0%

P/E Ratio

-0.07x

n/a

Debt / Equity

-0.16

n/a

Current Ratio

0.20

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of BCAB

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-7.00 · Revenue $5.59M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-7.00 · Revenue $4.80M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-46.00 · Revenue $19.70M · 1 analysts
Dec 31, 2027
FY2027 · Estimated annual results
Est. EPS $-58.50 · Revenue $3.60M · 1 analysts

Recent history

Aug 13, 2026
Q2 FY2026 · Results reported
EPS $0.27 · Revenue $6.50M
View filing
May 15, 2026
Q1 FY2026 · Results reported
EPS $-4.22 · Revenue $0.00
View filing
Mar 31, 2026
FY2025 · Annual results
EPS $-50.50 · Revenue $2.00M
View filing
Nov 13, 2025
Q3 FY2025 · Results reported
EPS $-13.50 · Revenue $0.00
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-16.00 · Revenue $0.00
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $-13.00 · Revenue $0.00
View filing

Financial Statements of BCAB

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$2.0M	-81.8%	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-59.6M	+14.6%	+107.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	-2053.7%	-2342.2%	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-2965.3%	-341.1%	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-2980.3%	-369.8%	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-48.2M	+33.0%	+92.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-2410.2%	-268.6%	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-17.1%	-392.3%	+0.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.37x	-89.6%	+35.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$13.8M	-73.6%	+11.0%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-50.50 vs -54.00	+6.5%	0.27 vs -8.50	+103.2%
Revenue Surprise	$2.0M vs $2.9M	-30.2%	$6.5M vs $6.5M	0.0%

Insider Transactions of BCAB

Acquisitions (A)

Since Mar 11, 2026

Disposals (D)

Since Mar 11, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 31, 2026	Sievers Eric	officer: Chief Medical Officer	Common Stock	D	134	$1.69
Aug 31, 2026	SHORT JAY M PHD	director, officer: Chief Executive Officer	Common Stock	D	259	$1.69
Aug 31, 2026	Vasquez Christian	officer: Chief Financial Officer	Common Stock	D	71	$1.69
May 31, 2026	Vasquez Christian	officer: Chief Financial Officer	Common Stock	D	82	$3.93
May 31, 2026	SHORT JAY M PHD	director, officer: Chief Executive Officer	Common Stock	D	259	$3.93

Earnings Call Transcript of BCAB

1 transcript segments

Q3 2025

Unknown Speaker

Operator: You all sites on hold. We appreciate your patience, and please continue to stand by. All sites on hold. We appreciate your patience, and please continue to stand by. Sites on hold. We appreciate your patience, and please continue to stand by. Good day, everyone, and welcome to today's BioAtla, Inc. Third Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. Later, you may have the opportunity to ask questions during the question and answer session. I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Julie Miller with LifeSci Advisors. Please go ahead. Julie Miller: Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla, Inc. are Dr. Jay M. Short, Chairman, CEO, and Co-founder; Dr. Eric L. Sievers, Chief Medical Officer; Sheri Lydick, Chief Commercial Officer; and Richard A. Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla, Inc. released financial results and a business update for the quarter ended 09/30/2025. A copy of the press release is available on the company's website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla, Inc.'s business plans and prospects, potential selective licensing, collaborations, and other strategic partnerships. The potential for our clinical trials to be registrational results, conduct progress, timing of our research and development programs and clinical trials, expectations with respect to enrollment and dosing in our clinical trials, the anticipated clinical benefits, safety, efficacy, and market potential of our product candidates, plans and expectations regarding future data updates, clinical trials, regulatory meetings, and regulatory submissions. The potential regulatory approval path for our product candidates, expectations about the sufficiency of our cash and cash equivalents, and expected R&D and G&A expenses. These statements are based on current expectations and are subject to various risks and uncertainties that can cause actual results to differ materially from those expressed or implied. These risks and uncertainties are described in our filings made with the SEC, including the most recent quarterly report on Form 10-Q and other subsequent filings. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of today, 11/13/2025. And BioAtla, Inc. disclaims any obligation to update or revise such statements to reflect new information, future events, or circumstances except as required by law. With that, I'd like to turn the call over to Jay M. Short. Jay? Jay M. Short: Thank you, Julie. And thanks to everyone for joining us for our third quarter 2025 BioAtla, Inc. earnings call. First and foremost, it is important to update that we are in advanced stages to finalize a …

Leadership Team of BCAB

9 executives

Name	Title	Compensation	Gender	Year Born	Status
Jay Short	Co-Founder, Chief Executive Officer & Chairman	USD 734,820	—	1958	Active
Eric L. Sievers	Chief Medical Officer	USD 530,630	—	1964	Active
Christian Vasquez	CFO, CAO, Controller & Corporate Secretary	USD 408,745	Male	1976	Active
Gerhard Frey	Senior Vice President of Technology Development	—	—	—	Active
Sheri Lydick	Chief Commercial Officer	—	Female	—	Active
Lisa Pelton	Accounting Manager	—	—	—	Active
Susie Melody	Senior Vice President of Human Resources	—	Female	—	Active
Cathy Chang	Senior Vice President of Research & Development	—	—	—	Active
Monica Sullivan	Senior Vice President of Intellectual Property & Contracts	—	Female	—	Active

Recent News of BCAB

GlobeNewsWire5/18/2026Neutral

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license

Historical Employee Count of BCAB

Current

Change

-32.79%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	41	10-K	Mar 31, 2026	View
Dec 31, 2024	61	10-K	Mar 28, 2025	View
Dec 31, 2023	65	10-K	Mar 26, 2024	View
Dec 31, 2022	66	10-K	Mar 23, 2023	View
Dec 31, 2021	56	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

BioAtla, Inc.

Contact Information

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

FY2026 · Estimated annual results

FY2027 · Estimated annual results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Recent Filings

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

FY2026 · Estimated annual results

FY2027 · Estimated annual results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Recent Filings